NEOMED Internal Medicine

Topics

• Multiple Myeloma Research and Treatments 146
• Systemic Lupus Erythematosus Research 39
• Pancreatitis Pathology and Treatment 21
• Inflammatory Bowel Disease 20
• Dialysis and Renal Disease Management 17
• Acute Kidney Injury Research 16
• Mechanical Circulatory Support Devices 15
• SARS-CoV-2 and COVID-19 Research 12
• CAR-T cell therapy research 11
• Cardiovascular Function and Risk Factors 10
• Chronic Obstructive Pulmonary Disease (COPD) Research 10
• Liver Disease and Transplantation 10

Most cited

1. Teclistamab in Relapsed or Refractory Multiple Myeloma.

   The New England journal of medicine · 2022 · 1,060 citations · Ajay Nooka

2. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

   The New England journal of medicine · 2023 · 653 citations · Ajay Nooka

3. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

   Nature medicine · 2023 · 572 citations · Ajay Nooka

4. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

   The New England journal of medicine · 2026 · 63 citations · Ajay Nooka

5. Systems vaccinology of the BNT162b2 mRNA vaccine in humans.

   Nature · 2021 · 461 citations · Shaurya Dhingra

6. New-onset IgG autoantibodies in hospitalized patients with COVID-19.

   Nature communications · 2021 · 390 citations · Shaurya Dhingra

7. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.